Risk Factors for Male Lower Urinary Tract Symptoms: The Role of Metabolic Syndrome and Androgenetic Alopecia in a Latin American Population

dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorBARBOSA, Joao Arthur B. A.
dc.contributor.authorMURACCA, Eduardo
dc.contributor.authorNAKANO, Elcio
dc.contributor.authorPARANHOS, Mario
dc.contributor.authorNATALINO, Renato
dc.contributor.authorCORDEIRO, Paulo
dc.contributor.authorSROUGI, Miguel
dc.contributor.authorANTUNES, Alberto Azoubel
dc.date.accessioned2013-09-23T16:30:06Z
dc.date.available2013-09-23T16:30:06Z
dc.date.issued2013
dc.description.abstractOBJECTIVE To evaluate the association of male lower urinary tract symptoms (LUTS) with metabolic syndrome (MetS) and androgenetic alopecia in a Latin American population. METHODS We enrolled 907 patients for prospective evaluation at a single institution. LUTS were evaluated with the International Prostate Symptom Score (IPSS). Subjects were evaluated with respect to hypertension, diabetes, dyslipidemia, previous cardiovascular events, body mass index (BMI), waist and hip circumference, and a laboratorial investigation including prostate-specific antigen (PSA), C-reactive protein (CRP), and gonadal steroids. Alopecia was classified according to the Norwood-Hamilton scale. RESULTS Mean patient age was 61.0 years; 57.5% of subjects had moderate/severe LUTS; MetS was present in 17.2% of subjects and 53.9% were classified as bald. Age, hypertension, diabetes, dyslipidemia, alopecia, previous cardiovascular event, and elevated waist-to-hip ratio (WHR) were associated with moderate/severe LUTS and with storage symptoms (P < .05). On multivariable analysis, age (odds ratio [OR] 2.30, 95% confidence interval [CI] 1.63-3.25), cardiovascular events (OR 1.73, 95% CI 1.07-2.78), and WHR (OR 1.65, 95% CI 1.13-2.40) were independent predictors for LUTS. For storage symptoms, age (OR 1.80, 95% CI 1.28-2.54), cardiovascular event (OR 2.07, 95% CI 1.27-3.39), WHR (OR 1.54, 95% CI 1.06-2.25), and MetS (OR 1.70, 95% CI 1.01-2.86) were independent risk factors. Age and cardiovascular event were the only independent predictors for voiding symptoms. CONCLUSION Components of the MetS were strongly associated with moderate and severe LUTS. WHR and cardiovascular events were independent predictors of voiding and storage symptoms, and MetS was an independent predictor of storage symptoms. Alopecia was not an independent predictor of LUTS. UROLOGY 82: 182-188, 2013. (C) 2013 Elsevier Inc.
dc.description.indexMEDLINE
dc.identifier.citationUROLOGY, v.82, n.1, p.182-188, 2013
dc.identifier.doi10.1016/j.urology.2013.03.001
dc.identifier.issn0090-4295
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1695
dc.language.isoeng
dc.publisherELSEVIER SCIENCE INC
dc.relation.ispartofUrology
dc.rightsrestrictedAccess
dc.rights.holderCopyright ELSEVIER SCIENCE INC
dc.subject.otherbenign prostatic hyperplasia
dc.subject.othermale pattern baldness
dc.subject.othersteroid-hormones
dc.subject.othermen
dc.subject.otherassociation
dc.subject.otherhealth
dc.subject.otherneurodegeneration
dc.subject.otherdutasteride
dc.subject.otherfinasteride
dc.subject.otherprevalence
dc.subject.wosUrology & Nephrology
dc.titleRisk Factors for Male Lower Urinary Tract Symptoms: The Role of Metabolic Syndrome and Androgenetic Alopecia in a Latin American Population
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus16
hcfmusp.contributor.author-fmusphcJOAO ARTHUR BRUNHARA ALVES BARBOSA
hcfmusp.contributor.author-fmusphcEDUARDO MURACCA YOSHINAGA
hcfmusp.contributor.author-fmusphcELCIO TADASHI NAKANO
hcfmusp.contributor.author-fmusphcMARIO LUIZ DA SILVA PARANHOS
hcfmusp.contributor.author-fmusphcRENATO ROMERA NATALINO
hcfmusp.contributor.author-fmusphcPAULO CORDEIRO
hcfmusp.contributor.author-fmusphcMIGUEL SROUGI
hcfmusp.contributor.author-fmusphcALBERTO AZOUBEL ANTUNES
hcfmusp.description.beginpage182
hcfmusp.description.endpage188
hcfmusp.description.issue1
hcfmusp.description.volume82
hcfmusp.origemWOS
hcfmusp.origem.pubmed23642850
hcfmusp.origem.scopus2-s2.0-84879553884
hcfmusp.origem.wosWOS:000321036200049
hcfmusp.publisher.cityNEW YORK
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceAlberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
hcfmusp.relation.referenceArias-Santiago S, 2012, J AM ACAD DERMATOL, V66, P401, DOI 10.1016/j.jaad.2010.12.023
hcfmusp.relation.referenceArias-Santiago S, 2010, J AM ACAD DERMATOL, V63, P420, DOI 10.1016/j.jaad.2009.10.018
hcfmusp.relation.referenceAzadzoi KM, 2007, J UROLOGY, V178, P710, DOI 10.1016/j.juro.2007.03.096
hcfmusp.relation.referenceCellek S, 1999, BRIT J PHARMACOL, V128, P1804, DOI 10.1038/sj.bjp.0702981
hcfmusp.relation.referenceChen WC, 2004, ARCH DERMATOL RES, V296, P245, DOI 10.1007/s00403-004-0514-z
hcfmusp.relation.referenceGao Y, 2012, UROLOGY, V79, P194, DOI 10.1016/j.urology.2011.07.1399
hcfmusp.relation.referenceGuarrera M, 2009, Int J Trichology, V1, P120, DOI 10.4103/0974-7753.58554
hcfmusp.relation.referenceGupta A, 2006, UROLOGY, V68, P1198, DOI 10.1016/j.urology.2006.09.034
hcfmusp.relation.referenceHammarsten J, 2001, EUR UROL, V39, P151, DOI 10.1159/000052430
hcfmusp.relation.referenceJin B, 1999, J CLIN ENDOCR METAB, V84, P3613, DOI 10.1210/jc.84.10.3613
hcfmusp.relation.referenceKupelian V, 2013, J UROLOGY, V189, pS107, DOI 10.1016/j.juro.2012.11.026
hcfmusp.relation.referenceLee RK, 2012, BJU INT, V110, P540, DOI 10.1111/j.1464-410X.2011.10819.x
hcfmusp.relation.referenceMontorsi F, 2011, BJU INT, V107, P1426, DOI 10.1111/j.1464-410X.2011.10129.x
hcfmusp.relation.referenceNeuhouser ML, 2004, UROLOGY, V64, P201, DOI 10.1016/j.urology.2004.04.025
hcfmusp.relation.referenceNickel JC, 2011, BJU INT, V108, P388, DOI 10.1111/j.1464-410X.2011.10195.x
hcfmusp.relation.referenceNORWOOD OT, 1975, SOUTHERN MED J, V68, P1359
hcfmusp.relation.referenceOh BR, 1998, UROLOGY, V51, P744, DOI 10.1016/S0090-4295(98)00108-3
hcfmusp.relation.referenceOhgaki K, 2011, UROLOGY, V77, P1432, DOI 10.1016/j.urology.2010.12.024
hcfmusp.relation.referenceRohrmann S, 2005, INT J OBESITY, V29, P310, DOI 10.1038/sj.ijo.0802881
hcfmusp.relation.referenceRossi A, 2011, DERMATOL THER, V24, P455, DOI 10.1111/j.1529-8019.2011.01441.x
hcfmusp.relation.referenceSeveri G, 2003, BRIT J DERMATOL, V149, P1207, DOI 10.1111/j.1365-2133.2003.05565.x
hcfmusp.relation.referenceShenfeld OZ, 2005, UROLOGY, V65, P181, DOI 10.1016/j.urology.2004.08.055
hcfmusp.relation.referenceSu LH, 2010, BRIT J DERMATOL, V163, P371, DOI 10.1111/j.1365-2133.2010.09816.x
hcfmusp.relation.referenceTemml C, 2009, UROLOGY, V73, P544, DOI 10.1016/j.urology.2008.10.027
hcfmusp.relation.referenceVignozzi L, 2012, J ENDOCRINOL, V212, P71, DOI 10.1530/JOE-11-0289
hcfmusp.relation.referenceYang TK, 2012, UROLOGY, V80, P1093, DOI 10.1016/j.urology.2012.08.002
hcfmusp.relation.referenceYip L, 2011, AUSTRALAS J DERMATOL, V52, P81, DOI 10.1111/j.1440-0960.2011.00745.x
hcfmusp.relation.referenceZhu YS, 2009, ANN NY ACAD SCI, V1155, P43, DOI 10.1111/j.1749-6632.2009.04115.x
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicationd86aaaca-3c92-4365-a8b4-94005dd9fecd
relation.isAuthorOfPublication9647b375-bd2a-4a6b-96ec-2658b78f13f8
relation.isAuthorOfPublicationb0abc86e-bf40-4b2b-98dc-ed2f1ec89aa7
relation.isAuthorOfPublicationd6db88cd-2c43-4c3f-a3f2-cc3ce9e0944b
relation.isAuthorOfPublication94132454-7351-4ce7-a3e8-9e874a8fe9e6
relation.isAuthorOfPublication33383df7-1a80-4828-b717-f2eddeb1063c
relation.isAuthorOfPublicationcff561dd-5732-4af5-abe9-538da0cdf4d2
relation.isAuthorOfPublication1e8c7153-c3dc-4c8f-8bf8-5e004f275e35
relation.isAuthorOfPublication.latestForDiscoveryd86aaaca-3c92-4365-a8b4-94005dd9fecd
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_BARBOSA_Risk_Factors_for_Male_Lower_Urinary_Tract_Symptoms_2013.PDF
Tamanho:
414.77 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)